MET and non-small cell lung carcinoma: Studies in NSCLC suggest that MET-amplified tumors often exhibit immune exclusion, which could further diminish responses to targeted therapy (49).Given the heterogeneity and clonal evolution of MET-amplified tumors, monotherapy with MET inhibitors like crizotinib may be insufficient for durable disease control.